Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study

Abstract

The objective of the study was to investigate the relation of different thyroid function states with the incidence of cardiovascular disease (CVD)/coronary heart disease (CHD) among a Middle-Eastern population with a high incidence of CVD/CHD. A total of 3975 participants entered the study (43.6% men). According to their thyroid stimulating hormone (TSH) and free thyroxin (FT4) levels, the participants were categorized into 5 groups: euthyroid, subclinical hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism, and overt hyperthyroidism. Multivariable Cox proportional hazard models were used to assess the relation of different thyroid function states with incident CVD/CHD, with euthyroid state as reference. The mean age (SD) of the participants was 46.5 (12.0) years. At baseline, no significant difference was observed in the frequency of prevalent CVD cases (n=201) between all groups. No significant interaction was found between prevalent CVD and different thyroid function states with outcomes, hence, we did not exclude participants with prevalent CVD from data analysis. A total of 400 CVD events (358 CHD cases) during a median follow-up of 11.2 years (inter-quartile range: 1.96) occurred. During the follow-up, even in the age and sex adjusted model, no association was observed between different states of thyroid dysfunction and incidence of CVD/CHD. The multivariable hazard ratios (95% CI) of subclinical hypothyroidism, hypothyroidism, subclinical hyperthyroidism, and hyperthyroidism for CVD events were 1.21 (0.77–1.88), 0.76 (0.33–1.69), 0.81 (0.46–1.41) and 1.48 (0.70–3.16), respectively. Both at baseline and during follow-up, no relation was observed between different states of thyroid function with prevalence and incidence of CVD/CHD.

Key words

hypothyroidism - hyperthyroidism - cardiovascular disease - subclinical

• References

• 1 Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367: 1747-1757
• 2 Eslami A, Mozaffary A, Derakhshan A, Azizi F, Khalili D, Hadaegh F. Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study. Int J Cardiol 2017; 227: 826-832
• 3 Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014; 11: 276
• 4 Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295: 1033-1041
• 5 Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB. Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 1999; 159: 237-245
• 6 Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29: 76-131
• 7 Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A, Taddei S, Palombo C, Ferrannini E. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2004; 89: 2099-2106
• 8 Grais IM, Sowers JR. Thyroid and the heart. Am J Med 2014; 127: 691-698
• 9 Jabbar A, Pingitore A, Pearce SHS, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14: 39-55
• 10 Volzke H, Robinson DM, Schminke U, Ludemann J, Rettig R, Felix SB, Kessler C, John U, Meng W. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab 2004; 89: 2145-2149
• 11 Sun X, Sun Y, Li WC, Chen CY, Chiu YH, Chien HY, Wang Y. Association of thyroid-stimulating hormone and cardiovascular risk factors. Intern Med (Tokyo, Japan) 2015; 54: 2537-2544
• 12 Chaker L, Ligthart S, Korevaar TI, Hofman A, Franco OH, Peeters RP, Dehghan A. Thyroid function and risk of type 2 diabetes: a population-based prospective cohort study. BMC Med 2016; 14: 150
• 13 Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010; 95: 1734-1740
• 14 Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C, Gislason GH. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99: 2372-2382
• 15 Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148: 832-845
• 16 Yang L-B, Jiang D-Q, Qi W-B, Zhang T, Feng Y-l, Gao L, Zhao J. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: An updated meta-analysis of cohort studies. Eur J Endocrinol 2012; 167: 75-84
• 17 Gencer B, Collet T-H, Virgini V, Auer R, Rodondi N. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. Endocr Metab Immun Disorders-Drug Targets 2013; 13: 4-12
• 18 Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008; 125: 41-48
• 19 Azizi F, Amouzegar A, Delshad H, Tohidi M, Mehran L. Natural course of thyroid disease profile in a population in nutrition transition: Tehran Thyroid Study. Archiv Iran Med 2013; 16: 418
• 20 Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, Mehrabi Y, Zahedi-Asl S. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials 2009; 10: 1
• 21 Amouzegar A, Delshad H, Mehran L, Tohidi M, Khafaji F, Azizi F. Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. J Endocrinol Invest 2013; 36: 950-954
• 22 Association AD . 2. Classification and diagnosis of diabetes. Diabetes Care 2016; 39: S13-S22
• 23 Hadaegh F, Harati H, Ghanbarian A, Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. European Journal of Cardiovascular Prev Rehabil 2006; 13: 571-577
• 24 Crunkhorn S, Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk?. Thyroid 2008; 18: 227-237
• 25 Sardarinia M, Akbarpour S, Lotfaliany M, Bagherzadeh-Khiabani F, Bozorgmanesh M, Sheikholeslami F, Azizi F, Hadaegh F. Risk Factors for Incidence of cardiovascular diseases and all-cause mortality in a middle eastern population over a decade follow-up: Tehran lipid and glucose study. PloS One 2016; 11: e0167623
• 26 Collet T-H, Gussekloo J, Bauer DC, Den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archiv Intern Med 2012; 172: 799-809
• 27 Chaker L, Baumgartner C, Ikram MA, Dehghan A, Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP, Franco OH. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol 2014; 29: 791-800
• 28 Lee JJ, Pedley A, Marqusee E, Sutherland P, Hoffmann U, Massaro JM, Fox CS. Thyroid function and cardiovascular disease risk factors in euthyroid adults: A Cross-sectional and longitudinal study. Clin Endocrinol 2016; 85: 932-941
• 29 Åsvold BO, Bjøro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT Study in Norway. Clin Endocrinol 2012; 77: 911-917
• 30 Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP, Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gussekloo J. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365-1374
• 31 Chaker L, Baumgartner C, den Elzen WP, Ikram MA, Blum MR, Collet TH, Bakker SJ, Dehghan A, Drechsler C, Luben RN, Hofman A, Portegies ML, Medici M, Iervasi G, Stott DJ, Ford I, Bremner A, Wanner C, Ferrucci L, Newman AB, Dullaart RP, Sgarbi JA, Ceresini G, Maciel RM, Westendorp RG, Jukema JW, Imaizumi M, Franklyn JA, Bauer DC, Walsh JP, Razvi S, Khaw KT, Cappola AR, Volzke H, Franco OH, Gussekloo J, Rodondi N, Peeters RP. Subclinical hypothyroidism and the risk of stroke events and fatal stroke: An individual participant data analysis. J Clin Endocrinol Metab 2015; 100: 2181-2191